跳至主要内容
临床试验/EUCTR2014-001022-14-NL
EUCTR2014-001022-14-NL进行中(未招募)1 期

An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes with ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

AbbVie Deutschland GmbH & Co. KG0 个研究点目标入组 1,650 人开始时间: 2014年11月26日最近更新:

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
1,650

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1. Males and females at least 18 years old at screening
  • 2. Females must be post-menopausal for more than 2 years or surgically sterile or practicing acceptable forms of birth control
  • 3. Chronic hepatitis C, genotype 1 infection
  • 4. Males must be surgically sterile or agree to practice acceptable forms of birth control
  • 5. Screening laboratory result indicating HCV genotype 1 infection.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 1470
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 180

排除标准

  • 1. Use of contraindicated medication within 2 weeks of dosing
  • 2. Abnormal laboratory tests
  • 3. Current or past clinical evidence of Child-Pugh B or C classification or history of liver decompensation
  • 4. Confirmed presence of hepatocellular carcinoma
  • 5. History of solid organ transplant

研究者

相似试验

进行中(未招募)
不适用
An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes with ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) InfectioChronic Hepatitis C InfectionMedDRA version: 17.0Level: PTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestations
EUCTR2014-001022-14-ITAbbVie Deutschland GmbH & Co. KG1,650
已完成
3 期
An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I).chronische hepatitis C-virusinfectieChronic Hepatitis C Virus Infectioninfectious disease affecting primarily the liver10047438
NL-OMON55830AbbVie Ltd.21
进行中(未招募)
1 期
An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes with ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) InfectioChronic Hepatitis C InfectionMedDRA version: 17.1Level: PTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestations
EUCTR2014-001022-14-SEAbbVie Deutschland GmbH & Co. KG1,650
进行中(未招募)
1 期
An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes with ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infectio
EUCTR2014-001022-14-DKAbbVie Deutschland GmbH & Co. KG1,650
进行中(未招募)
1 期
An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes with ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infectio
EUCTR2014-001022-14-DEAbbVie Deutschland GmbH & Co. KG1,650
An Open-Label, Multicenter Study to Evaluate... | 临床试验